This subclone contained missense mutations in the TP53 regulator MDM4, as well as FIP1L1, an oncogenic driver in prostate cancer, POU2AF1, a transcriptional activator in Hodgkin’s disease and frameshift mutations in IFI16, which modulates TP53 and RAS/RAF signalling. Here, IFI16 is linked to prostate carcinoma.